A second round of anti-CD19 CAR T-cell therapy in diffuse large B-cell lymphoma: when persistence pays off

Click to increase image sizeClick to decrease image size

Acknowledgements

This research did not receive any specific funding from agencies or organizations in the public, commercial, or not-for-profit sectors. The authors thank Dr David Fraser (Biotech Communication SARL, Ploudalmézeau, France) for copy-editing assistance.

Authors contributions

ML, LD, MP, NS and DB designed the study; ML, LD and DB wrote the initial draft of the manuscript; LD designed the figure; JD performed the flow cytometric analysis; EKA. reported viral quantitative data; DB, MN, DC, WAC, FM and IYA reported clinical data; ML, LD, MP, PO and NS reported pharmacological data. All authors read and approved the final manuscript.

Disclosure statement

FM: Kite/Gilead (consultancy), Novartis (consultancy)

DB: Kite/Gilead (honoraria, consultancy)

The other authors declare no competing financial interests.

Data availability statement

The data that support the findings of this study are available on request from the corresponding author.

Additional information

Funding

The author(s) reported there is no funding associated with the work featured in this article.